Eurofins Dermscan Pharmascan
Villeurbanne, France
NCT Number: NCT06047145
This double-blind, placebo-controlled, randomised pilot trial aims to assess the effect of oral soy isoflavone consumption on skin ageing parameters in post-menopausal women.
Looking for future studies?
Notify Me40 year–65 year
Female
Interventional
Not applicable
Villeurbanne, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 capsule daily for 84 days
1 capsule daily for 84 days
Time frame: day 0, day 84
Cutaneous relief parameters (Ra - Average roughness) on Crow's Feet wrinkles measured with fringe projection acquisitions
Time frame: day 0, day 42
Cutaneous relief parameters (Ra - Average roughness) on Crow's Feet wrinkles measured with fringe projection acquisitions
Time frame: day 0, day 42, day 84
Cutaneous relief parameters (Rz - Average height of the roughness) on Crow's Feet wrinkles measured with fringe projection acquisitions
Time frame: day 0, day 42, day 84
Cutaneous relief parameters (Rt - Maximum height of the roughness profile) on Crow's Feet wrinkles measured with fringe projection acquisitions
Time frame: day 0, day 42, day 84
Cutaneous relief parameters (Ra - Average roughness) on under eye wrinkles measured with fringe projection acquisitions
Time frame: day 0, day 42, day 84
Cutaneous relief parameters (Rt - Maximum height of the roughness profile) on under eye wrinkles measured with fringe projection acquisitions
Time frame: day 0, day 42, day 84
Cutaneous relief parameters (Rz - Average height of the roughness) on under eye wrinkles measured with fringe projection acquisitions
Time frame: day 0, day 42, day 84
Skin hydration will be evaluated by Corneometer® on the forearm.
Time frame: day 0, day 42, day 84
Skin colour will be evaluated by Spectrophotometer® on the cheekbone.
Time frame: day 0, day 42, day 84
Skin barrier function will be evaluated by the measurement of Trans Epidermal Water Loss with Aquaflux® on the forearm
Time frame: day 42, day 84
A non-validated subjective evaluation questionnaire on the study product's effects on the skin will be completed by subjects (each item is scored individually on a 5 point Likert scale ranging from 'Totally agree' to 'Totally disagree')
Time frame: day 0, day 42, day 84
Collection of adverse events throughout the study
Time frame: day 0, day 42, day 84
To quantify levels of key isoflavones and metabolites in urine
Time frame: day 0, day 42, day 84
To identify equol-producing individuals based on urine levels of equol
The Archer-Daniels-Midland Company
Industry
Evaluation of Oral Soy Isoflavone Concentrates on Skin Ageing Parameters: a Double-blind Randomised Placebo-controlled Trial
Acronym: ISOSKIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07501000
Hyperpigmentation, Pigmentation Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT07572331
Acne, Acne Vulgaris
Beverly, Massachusetts, United States
View Trial DetailsNCT07521423
Healthy Ageing, Oxidative Stress
Athens, Attica, Greece
View Trial DetailsNCT07302789
Facial Wrinkles - Rough Texture - Hyperpigmentation, Skin Ageing
Valencia, Spain
View Trial Details